This strategy aids in minimizing damage to thymic epithelial cells, sustains thymic selection, and concurrently preserves the graft‐versus‐leukemia response.[114] Additionally, it is reported that treatment with anti‐TRBV9 antibodies may result in the elimination of human TRBV9+ T cells in an AS patient, who achieved remission in three months and has been sustained for four years.[115]. The gene discussed is TRBV9; the disease is leukemia.